RxDoctor Payments Data

Henry Querfurth, MD

Neurology · Brighton, MANPI 1336135649

Payments from drug & device makers

$223,217in general payments, 2019–2025

Across 61 payments — averaging $3659.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$168K
  • Eli Lilly$54K
  • Sunovion Pharmaceuticals Inc.$532
  • Teva Pharmaceuticals USA, Inc.$205
  • Eisai Inc.$119
  • Biohaven Pharmaceuticals, Inc.$97
  • plus $400 from 12 others
$700in research payments, 2019–2025

Across 2 payments — averaging $350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$700

What the payments were for

  • Speaking & faculty fees$564%
  • Food & beverage$1,24488%
  • Education$1218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$223,217 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$33,989
Medicare patients
175
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate11$55,713
UbrelvyUbrogepant20$21,267
RexultiBrexpiprazole11$18,142
Aimovig AutoinjectorErenumab-Aooe16$11,282
Rivastigmine45$7,700
Galantamine ErGalantamine Hbr90$6,330
Memantine Hcl ErMemantine Hcl87$4,665
Donepezil Hcl269$2,750
Memantine Hcl30$1,927
Pregabalin12$1,300
Propranolol Hcl ErPropranolol Hcl18$813
Carbidopa-LevodopaCarbidopa/Levodopa41$735
Gabapentin34$252
Risperidone14$221
Sertraline Hcl20$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$28$21,26720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Brighton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →